Molnupiravir: everything you need to know about the new Covid pill
UK approves ‘game-changer’ medication for at-risk patients to take at home

The UK has become the first country to approve the use of an oral medication that can be taken at home to treat Covid-19.
Molnupiravir was given the green light today by the UK’s regulatory body for medicines. The pill “will be a game-changer for the most vulnerable and the immunosuppressed”, said Health Secretary Sajid Javid.
Who will get it?
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The oral antiviral, developed by two US companies – Ridgeback Biotherapeutics and Merck, Sharp & Dohme – has been approved for use by patients with mild to moderate cases of Covid who also present at least one risk factor. Elderly people, diabetics and people with heart disease will be among the first to be offered the treatment.
How does it work?
Molnupiravir works by targeting the enzyme that is responsible for causing the coronavirus to replicate within the body by “introducing errors into its genetic code”, said the BBC. “That should prevent it from multiplying, so keeping virus levels low in the body and reducing the severity of the disease.” Patients can self-administer the medication twice a day, and it is best taken within the first five days of symptoms presenting.
How effective is it?
Clinical trial data showed that the pill “cut the risk of hospitalisation or death by about half” for people at increased risk of developing severe cases of Covid, said the BBC. The Medicines and Healthcare products Regulatory Agency (MHRA) has deemed the treatment both “safe and effective”, with chief executive June Raine describing the medicine as “another therapeutic to add to our armoury against Covid-19”, Sky News reported.
How much does it cost?
The UK has already ordered 480,000 courses of molnupiravir to arrive by the end of the year. Reuters reported that an order for roughly half that amount has also been placed for a similar drug being developed by Pfizer.
The government “has not disclosed” how much the initial Merck, Sharp and Dohme contract has cost, but US authorities struck a deal that worked out at around $700 (£513) per patient, the BBC said. Australia, Singapore and South Korea have also placed orders for the drug.
How long will it take to roll out?
The health secretary said the government is “working at pace” with the NHS to lay out plans to “deploy” the drug to patients “as soon as possible”. He added that it is still “vital” everyone receives a “life-saving Covid-19 vaccine”, as molnupiravir is not a substitute for vaccination.
Penny Ward, a professor in pharmaceutical medicine at King's College London, told the BBC that if trial results are replicated in the UK, “the number of cases requiring hospital admission could be halved and the number of deaths greatly reduced”.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Today's political cartoons - April 19, 2025
Cartoons Saturday's cartoons - free trade, judicial pushback, and more
By The Week US
-
5 educational cartoons about the Harvard pushback
Cartoons Artists take on academic freedom, institutional resistance, and more
By The Week US
-
One-pan black chickpeas with baharat and orange recipe
The Week Recommends This one-pan dish offers bold flavours, low effort and minimum clean up
By The Week UK
-
The sneaking rise of whooping cough
Under the Radar The measles outbreak isn't the only one to worry about
By Theara Coleman, The Week US
-
Washwood Heath: Birmingham's pioneering neighbourhood health service
In the Spotlight NHS England chair says there is a 'really good argument this is the model for the future'
By The Week UK
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
By The Week US
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US
-
The UK's first legal drug consumption room
The Explainer 'Potentially transformative moment in UK drugs policy' as The Thistle opens in Glasgow
By The Week UK
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US
-
How can the UK solve the adult social care crisis?
Today's Big Question New commission announced to turn our buckling care sector around: yet more delay or finally a way forward?
By Elizabeth Carr-Ellis, The Week UK